Figures & data
Figure 1. Study flowchart. TT: tailored therapy; BQT: bismuth quadruple therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol.
![Figure 1. Study flowchart. TT: tailored therapy; BQT: bismuth quadruple therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol.](/cms/asset/4c78f8da-01a6-46ca-9130-11d77afbd1de/igas_a_1948606_f0001_b.jpg)
Figure 2. Flowchart of patients in the tailored therapy group. TT: tailored therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol; BQT: bismuth quadruple therapy.
![Figure 2. Flowchart of patients in the tailored therapy group. TT: tailored therapy; ITT: intention-to-treat; mITT: modified intention-to-treat; PP: per protocol; BQT: bismuth quadruple therapy.](/cms/asset/652ac6e9-9d7a-473d-ba86-8c7199c70e5b/igas_a_1948606_f0002_b.jpg)
Table 1. Basic characteristics of patients in the two study groups.
Table 2. Helicobacter pylori eradication efficacies in the two groups.
Table 3. Compliance and adverse events in the two groups.
Data availability statement
All data generated or analyzed during this study are included in this published article.